3C-AL, also known as 4-allyloxy-3,5-dimethoxyamphetamine or as ñ-methylallylescaline (3C-allylescaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA). It is the amphetamine (3C) analogue of allylescaline.
The drug has a dose range of 15 to 30mg orally and a duration of 8 to 12hours. Its effects have been described as more visual than those of allylescaline.
The drug is a potent partial agonist of the serotonin 5-HT<sub>2A</sub> receptor and also interacts with other serotonin receptors and targets.
The chemical synthesis of 3C-AL has been described.
3C-AL was described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), but he did not synthesize or test 3C-AL. Instead, Daniel Trachsel synthesized 3C-AL in 2002 and described its properties and effects in 2013. The pharmacology of 3C-AL was studied in greater detail in 2021. It is a controlled substance in Canada under amphetamine blanket-ban language.